Intrinsic Value of S&P & Nasdaq Contact Us

NewcelX Ltd. NCEL NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • CH • USD

SharesGrow Score
66/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

NewcelX Ltd. (NCEL) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.

Analysts estimate Earnings Per Share (EPS) of $-16.00 and revenue of $0.00B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-26.30 vs est $-16.00 (missed -64.4%). Analyst accuracy: 61%.

NCEL Analyst Ratings

Buy
2
Ratings
2 Buy
Based on 2 analysts giving stock ratings to NewcelX Ltd. in the past 3 months
Rating breakdown
Buy
2 100%
100%
Buy
2 analysts
0%
Hold
0 analysts
0%
Sell
0 analysts

EPS Estimates — NCEL

61%
Analyst Accuracy
Fair
1 year compared
Actual vs Estimate
2024 Actual –$26.30 vs Est –$16.00 ▼ 39.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.

Revenue Estimates — NCEL

Revenue Trend
Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message